Opendata, web and dolomites

AutArt

Clinical validation of the AutArt rheumatoid arthritis diagnostic device

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AutArt project word cloud

Explore the words cloud of the AutArt project. It provides you a very rough idea of what is the project "AutArt" about.

2020    heijde    union    became    decreased    modifying    service    rheumatoid    intensive    considerably    sustainability    regular    sharp    group    image    act    arthritis    serious    30    permanently    50    chronic    der    social    device    cartilage    ten    biologic    points    precision    validation    sas    causes    disabled    dynamically    diagnosis    medical    selling    scheduled    consists    estimate    line    diagnostic    scoring    causing    autoimmune    objectivity    agents    2014    2009    healthcare    282    van    diagnoses    feasibility    first    joints    sold    rising    patients    contributes    health    provides    precise    drugs    clinical    competitors    economic    pharmaceutical    million    destroy    ra    successful    billion    regulation    progression    toolkit    automatically    comparability    eur    people    millions    moment    market    bone    companies    evaluation    action    25    ray    software    inflammation    mds    autart    sale    monitoring    lining    treatment    detection    ineffective    establishment    15    time    disease    share    deformity    treatments    follow   

Project "AutArt" data sheet

The following table provides information about the project.

Coordinator
BIFARMA SZOFTVERFEJLESZTO ES TANACSADO KORLATOLT FELELOSSEGU TARSASAG 

Organization address
address: SZABOLCSKA MIHALY UTCA 1 FSZT 3
city: BUDAPEST
postcode: 1114
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Hungary [HU]
 Project website http://www.bifarma.hu
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIFARMA SZOFTVERFEJLESZTO ES TANACSADO KORLATOLT FELELOSSEGU TARSASAG HU (BUDAPEST) coordinator 50˙000.00

Map

 Project objective

The AutArt diagnostic toolkit is a medical device that automatically diagnoses the progression of Rheumatoid Arthritis (RA) on an X-Ray image by using the Sharp/van der Heijde scoring system. This Phase 1 feasibility study will support the clinical validation of the device in Phase 2 that we estimate will cost between 1.5-2 million EUR; with the first market sale scheduled within 2 years, sold SAS (Software as a Service). RA is a chronic autoimmune disease that causes inflammation of the lining of the joints, which can destroy cartilage and bone, causing deformity of the joints. RA is a serious economic and social problem, 20-30% of early RA patients become permanently work disabled during the first 2-3 years of the disease and more than 50% of patients with RA became work disabled during the first ten years of the disease. Classical disease-modifying drugs are ineffective in about 10-15% of the cases, furthermore, biologic agents may also be ineffective. Early detection, regular clinical monitoring and comparable, objective evaluation is essential for successful treatment. The AutArt medical device is the result of 2 years of intensive R&D and at the moment there are no serious competitors in the market, so this is the time to act for a dynamically rising market share in the RA diagnostic market. The target group consists of MDs, medical institutions and pharmaceutical companies. The unique selling points of the product are objectivity, comparability and precision. In the EU, RA treatments cost 25.1 billion EUR in 2009. With more precise diagnosis and objective follow-up this can be decreased considerably with the AutArt medical device. This project is in line with the 282/2014/EU regulation on the establishment of a third Programme for the Union’s action in the field of health (2014-2020) because it contributes to the sustainability of the healthcare system and provides millions of people with better treatment through more precise diagnosis.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AUTART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AUTART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More